{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:04:11Z","timestamp":1791551051950,"version":"4.3.4"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology Cardiovascular Risk and Prevention"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ijcrp.2021.200121","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T17:57:27Z","timestamp":1636826247000},"page":"200121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Hypertension and its management in COVID-19 patients: The assorted view"],"prefix":"10.1016","volume":"11","author":[{"given":"Gaber El-Saber","family":"Batiha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahim","family":"Gari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norhan","family":"Elshony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5931-0466","authenticated-orcid":false,"given":"Hazem M.","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7666-4776","authenticated-orcid":false,"given":"Murtala Bello","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5924-9391","authenticated-orcid":false,"given":"Sherif Babatunde","family":"Adeyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcrp.2021.200121_bib1","first-page":"101","article-title":"Is ivermectin\u2013Azithromycin combination the next step for COVID-19? Biomed","volume":"4","author":"Al-Kuraishy","year":"2020","journal-title":"Biotechnol. Res. J."},{"key":"10.1016\/j.ijcrp.2021.200121_bib2","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2020.03.031","article-title":"Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic","volume":"75","author":"Driggin","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib3","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1161\/HYPERTENSIONAHA.120.15312","article-title":"Renin-angiotensin-aldosterone system inhibitors and outcome in patients with SARS-CoV-2 pneumonia: a case series study","volume":"76","author":"Conversano","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcrp.2021.200121_bib4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ijcrp.2021.200121_bib5","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ijcrp.2021.200121_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117905","article-title":"Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to macrophage activation syndrome: therapeutic implications","volume":"256","author":"Banu","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ijcrp.2021.200121_bib7","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijcrp.2021.200121_bib8","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1093\/gerona\/glaa146","article-title":"Clinical characteristics of hospitalized individuals dying with COVID-19 by age group in Italy","volume":"75","author":"Palmieri","year":"2020","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"10.1016\/j.ijcrp.2021.200121_bib9","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcrp.2021.200121_bib10","doi-asserted-by":"crossref","first-page":"F1526","DOI":"10.1152\/ajprenal.00149.2018","article-title":"The chemokine receptor CX3CR1 reduces renal injury in mice with angiotensin II-induced hypertension","volume":"315","author":"Ahadzadeh","year":"2018","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib11","article-title":"Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients","author":"Liu","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.ijcrp.2021.200121_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpu086","article-title":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker","volume":"28","author":"Furuhashi","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcrp.2021.200121_bib13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12471-020-01439-5","article-title":"Renin-angiotensin system inhibition in COVID-19 patients","volume":"28","author":"de Vries","year":"2020","journal-title":"Neth. Heart J."},{"key":"10.1016\/j.ijcrp.2021.200121_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/cpt.1863","article-title":"Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence","volume":"108","author":"Sriram","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijcrp.2021.200121_bib15","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","article-title":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study","volume":"41","author":"Gao","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcrp.2021.200121_bib16","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3389\/fimmu.2020.01206","article-title":"Could SARS-CoV-2-induced hyperinflammation magnify the severity of coronavirus disease (CoViD-19) leading to acute respiratory distress syndrome?","volume":"11","author":"Girija","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib17","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2666-5247(20)30172-5","article-title":"SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis","volume":"2","author":"Cevik","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijcrp.2021.200121_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.644295","article-title":"COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type ii diabetes mellitus: the anti-inflammatory role of metformin","volume":"8","author":"Al-Kuraishy","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ijcrp.2021.200121_bib19","first-page":"1775","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","volume":"323","author":"Onder","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ijcrp.2021.200121_bib20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.119.13133","article-title":"ACE2 and ADAM17 interaction regulates the activity of presympathetic neurons","volume":"74","author":"Mukerjee","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcrp.2021.200121_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4103\/bbrj.bbrj_105_20","article-title":"Renin\u2013Angiotensin system and fibrinolytic pathway in COVID-19: one-way skepticism","volume":"4","author":"Al-Kuraishy","year":"2020","journal-title":"Biomed. Biotechnol. Res. J."},{"key":"10.1016\/j.ijcrp.2021.200121_bib22","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3201\/eid2609.202095","article-title":"Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States","volume":"26","author":"Martines","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ijcrp.2021.200121_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-03015-0","article-title":"Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients","volume":"24","author":"Wu","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.ijcrp.2021.200121_bib24","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1093\/eurheartj\/ehaa534","article-title":"Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19","volume":"41","author":"Gue","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcrp.2021.200121_bib25","first-page":"12493","article-title":"Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis","volume":"12","author":"Fang","year":"2020","journal-title":"Aging (Albany N. Y.)."},{"key":"10.1016\/j.ijcrp.2021.200121_bib26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1042\/CS20200163","article-title":"Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?","volume":"134","author":"Batlle","year":"2020","journal-title":"Clin. Sci."},{"key":"10.1016\/j.ijcrp.2021.200121_bib27","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019\u2014COVID-NET, 14 States, March 1\u201330, 2020","volume":"69","author":"Garg","year":"2020","journal-title":"MMWR (Morb. Mortal. Wkly. Rep.)"},{"key":"10.1016\/j.ijcrp.2021.200121_bib28","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcrp.2021.200121_bib29","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2020.2565","article-title":"Presumed asymptomatic carrier transmission of COVID-19","volume":"323","author":"Bai","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ijcrp.2021.200121_bib30","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(20)30627-9","article-title":"COVID-19 and Italy: what next?","volume":"395","author":"Andrea","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijcrp.2021.200121_bib31","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1253\/circj.CJ-20-0881","article-title":"Human-induced pluripotent stem cell-derived cardiomyocytes platform to study SARS-CoV-2 related myocardial injury","volume":"84","author":"Wong","year":"2020","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcrp.2021.200121_bib32","doi-asserted-by":"crossref","first-page":"30113","DOI":"10.1074\/jbc.M505111200","article-title":"Tumor necrosis factor-\u03b1 convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)","volume":"280","author":"Lambert","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcrp.2021.200121_bib33","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1172\/JCI138554","article-title":"Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent","volume":"130","author":"Mazzoni","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijcrp.2021.200121_bib34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.HYP.0000113044.46326.98","article-title":"Reduced endothelial NO-cGMP\u2013mediated vascular relaxation and hypertension in IL-6\u2013infused pregnant rats","volume":"43","author":"Orshal","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcrp.2021.200121_bib35","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/jhh.2017.7","article-title":"Hypomethylation of interleukin-6 (IL-6) gene increases the risk of essential hypertension: a matched case\u2013control study","volume":"31","author":"Mao","year":"2017","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ijcrp.2021.200121_bib36","first-page":"936","article-title":"Computer-aided prediction and design of IL-6 inducing peptides: IL-6 plays a crucial role in COVID-19. Brief","volume":"22","author":"Dhall","year":"2021","journal-title":"Bioinformation"},{"key":"10.1016\/j.ijcrp.2021.200121_bib37","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/bph.14427","article-title":"Role of immune cells in hypertension","volume":"176","author":"Caillon","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib38","first-page":"1","article-title":"Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study","volume":"5","author":"Tan","year":"2020","journal-title":"Signal Transduct. Targeted Therapy"},{"key":"10.1016\/j.ijcrp.2021.200121_bib39","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/cvr\/cvy001","article-title":"Deoxycorticosterone acetate-salt hypertension activates placental growth factor in the spleen to couple sympathetic drive and immune system activation","volume":"114","author":"Perrotta","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcrp.2021.200121_bib40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fphys.2012.00128","article-title":"Vascular inflammatory cells in hypertension","volume":"3","author":"Harrison","year":"2012","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd6197","article-title":"Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19","volume":"5","author":"Mann","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib42","doi-asserted-by":"crossref","first-page":"8019360","DOI":"10.1155\/2020\/8019360","article-title":"Arterial hypertension as a risk comorbidity associated with COVID-19 pathology","volume":"2020","author":"Kamyshnyi","year":"2020","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.ijcrp.2021.200121_bib43","series-title":"Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients","author":"Chen","year":"2020"},{"key":"10.1016\/j.ijcrp.2021.200121_bib44","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41587-020-00796-1","article-title":"Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19","volume":"39","author":"Trump","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib45","first-page":"304","article-title":"Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis","volume":"130","author":"Lippi","year":"2020","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.ijcrp.2021.200121_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11906-020-01057-x","article-title":"Is hypertension a real risk factor for poor prognosis in the COVID-19 pandemic?","volume":"22","author":"Drager","year":"2020","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ijcrp.2021.200121_bib47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/HYPERTENSIONAHA.114.03617","article-title":"Aging, arterial stiffness, and hypertension","volume":"65","author":"Sun","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcrp.2021.200121_bib48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis","volume":"94","author":"Yang","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ijcrp.2021.200121_bib49","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.117.032380","article-title":"Status of hypertension in China: results from the China hypertension survey, 2012\u20132015","volume":"137","author":"Wang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcrp.2021.200121_bib50","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.clnu.2017.05.012","article-title":"Association of general and central obesity with hypertension","volume":"37","author":"Nurdiantami","year":"2018","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.ijcrp.2021.200121_bib51","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/oby.22818","article-title":"Obesity and its implications for COVID-19 mortality","volume":"28","author":"Dietz","year":"2020","journal-title":"Obesity"},{"key":"10.1016\/j.ijcrp.2021.200121_bib52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.120.047659","article-title":"Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms","volume":"142","author":"Sattar","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ijcrp.2021.200121_bib53","doi-asserted-by":"crossref","first-page":"408","DOI":"10.5455\/jice.20160815080732","article-title":"Effect of orlistat alone or in combination with Garcinia cambogia on visceral adiposity index in obese patients","volume":"5","author":"Al-Kuraishy","year":"2016","journal-title":"J. Intercult. Ethnopharmacol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/diseases6010009","article-title":"Rosuvastatin improves vaspin serum levels in obese patients with acute coronary syndrome","volume":"6","author":"Al-kuraishy","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.ijcrp.2021.200121_bib55","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/0976-0105.195080","article-title":"Effects of rosuvastatin alone or in combination with omega-3 fatty acid on adiponectin levels and cardiometabolic profile","volume":"8","author":"Al-Kuraishy","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.ijcrp.2021.200121_bib56","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3390\/cells10040933","article-title":"Obesity as a risk factor for severe COVID-19 and complications: a review","volume":"10","author":"Demeulemeester","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ijcrp.2021.200121_bib57","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/jmv.26237","article-title":"Obesity aggravates COVID\u201019: a systematic review and meta\u2010analysis","volume":"93","author":"Yang","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib58","first-page":"113","article-title":"Levothyroxine improves Paraoxonase (PON-1) serum levels in patients with primary hypothyroidism: case\u2013control study","volume":"9","author":"Al-Naimi","year":"2018","journal-title":"\"J. Adv. Pharm. Technol. Research\"\" (JAPTR)\""},{"key":"10.1016\/j.ijcrp.2021.200121_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23923","article-title":"Risk factors for prolonged virus shedding of respiratory tract and fecal in adults with severe acute respiratory syndrome coronavirus\u20102 infection","volume":"35","author":"Zhang","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.ijcrp.2021.200121_bib60","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.clnu.2021.02.038","article-title":"Obesity pandemic during COVID-19 outbreak: narrative review and future considerations","volume":"40","author":"Cava","year":"2021","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.ijcrp.2021.200121_bib61","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/jamainternmed.2020.5415","article-title":"Regardless of age, obesity and hypertension increase risks with COVID-19","volume":"181","author":"Katz","year":"2021","journal-title":"JAMA Int. Med."},{"key":"10.1016\/j.ijcrp.2021.200121_bib62","article-title":"Assessment of NF-\u03baB inhibitor (SN50) effect on adipose tumor necrosis factor-alpha and angiotensinogen secretion and expression","author":"Al-Dagheri","year":"2021","journal-title":"Preprints"},{"key":"10.1016\/j.ijcrp.2021.200121_bib63","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.dsx.2020.04.033","article-title":"SARS-CoV-2 infection and obesity: common inflammatory and metabolic aspects","volume":"14","author":"Michalakis","year":"2020","journal-title":"Diabetes Metabol. Syndrome: Clin. Res. Rev."},{"key":"10.1016\/j.ijcrp.2021.200121_bib64","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.3389\/fimmu.2020.570251","article-title":"NLRP3 inflammasome: the stormy link between obesity and COVID-19","volume":"11","author":"L\u00f3pez-Reyes","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib65","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/13880209.2021.1953541","article-title":"Huoxue Qianyang Qutan recipe attenuates cardiac fibrosis by inhibiting the NLRP3 inflammasome signalling pathway in obese hypertensive rats","volume":"59","author":"Lu","year":"2021","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib66","doi-asserted-by":"crossref","first-page":"e3074","DOI":"10.1038\/cddis.2017.470","article-title":"NLRP3 inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension","volume":"8","author":"Sun","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ijcrp.2021.200121_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104906","article-title":"COVID-19, hypertension and cardiovascular diseases: should we change the therapy?","volume":"158","author":"Tadic","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijcrp.2021.200121_bib68","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41581-020-00357-4","article-title":"Immunity, endothelial injury and complement-induced coagulopathy in COVID-19","volume":"17","author":"Perico","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib69","first-page":"201","article-title":"COVID-19 with different severity: a multi-center study of clinical features","author":"Yun","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijcrp.2021.200121_bib70","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","volume":"5","author":"Li","year":"2020","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib71","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.ijcrp.2021.200121_bib72","first-page":"1","article-title":"Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID\u201019, inflammation level, severity, and death in patients with COVID\u201019: a rapid systematic review and meta\u2010analysis","author":"Liu","year":"2020","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib73","article-title":"Retinal angiotensin II and angiotensin-(1-7) response to hyperglycemia and an intervention with captopril","volume":"19","author":"Senanayake","year":"2018","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS"},{"key":"10.1016\/j.ijcrp.2021.200121_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jtm\/taaa041","article-title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","volume":"27","author":"Diaz","year":"2020","journal-title":"J. Trav. Med."},{"key":"10.1016\/j.ijcrp.2021.200121_bib75","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1017\/ice.2020.80","article-title":"A potential protective role of losartan against coronavirus-induced lung damage","volume":"41","author":"Zeinalian","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib76","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ijcrp.2021.200121_bib77","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/jch.14011","article-title":"Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol","volume":"22","author":"Cohen","year":"2020","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ijcrp.2021.200121_bib78","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1093\/cvr\/cvaa325","article-title":"COVID-19, hypertension, and RAAS blockers: the BRACE-CORONA trial","volume":"116","author":"Mancia","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcrp.2021.200121_bib79","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S2213-2600(21)00214-9","article-title":"Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial","volume":"9","author":"Bauer","year":"2021","journal-title":"Lancet Respirat. Med."},{"key":"10.1016\/j.ijcrp.2021.200121_bib80","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1113\/JP271516","article-title":"Sympathetic\u2010mediated activation versus suppression of the immune system: consequences for hypertension","volume":"594","author":"Case","year":"2016","journal-title":"J. Physiol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.639222","article-title":"Hypertension and COVID-19: ongoing controversies","volume":"8","author":"Tadic","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ijcrp.2021.200121_bib82","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/jch.14146","article-title":"Independent and combined effects of hypertension and diabetes on clinical outcomes in patients with COVID\u201019: a retrospective cohort study of Huoshen Mountain Hospital and Guanggu Fangcang Shelter Hospital","volume":"23","author":"Sun","year":"2021","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.ijcrp.2021.200121_bib83","series-title":"Selected Chapters from the Reninangiotensin System","first-page":"151","article-title":"The potential role of renin angiotensin system (RAS) and dipeptidyl peptidase-4 (DPP-4) in COVID-19: navigating the uncharted","author":"Al-Kuraishy","year":"2020"},{"key":"10.1016\/j.ijcrp.2021.200121_bib84","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/infdis\/jiaa332","article-title":"ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19","volume":"222","author":"Pinto","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijcrp.2021.200121_bib85","doi-asserted-by":"crossref","first-page":"F398","DOI":"10.1152\/ajprenal.90488.2008","article-title":"Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan","volume":"296","author":"Soler","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib86","first-page":"450","article-title":"Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV","volume":"48","author":"Peng","year":"2020","journal-title":"Zhonghua Xinxueguanbing Zazhi"},{"key":"10.1016\/j.ijcrp.2021.200121_bib87","first-page":"203","article-title":"Observations on clinical treatment of COVID-19 complicated with cardiovascular disease","volume":"36","author":"Haoyang","year":"2021","journal-title":"Clinical Focus"},{"key":"10.1016\/j.ijcrp.2021.200121_bib88","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41569-020-0401-0","article-title":"RAAS inhibitors do not increase the risk of COVID-19","volume":"17","author":"Fern\u00e1ndez-Ruiz","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109776","article-title":"Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?","volume":"140","author":"Carboni","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ijcrp.2021.200121_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25092076","article-title":"Pharmacological (or synthetic) and nutritional agonists of PPAR-\u03b3 as candidates for cytokine storm modulation in COVID-19 disease","volume":"25","author":"Ciavarella","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ijcrp.2021.200121_bib91","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/07391102.2016.1227726","article-title":"Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-\u03b3 by core hopping of telmisartan","volume":"35","author":"Zhang","year":"2017","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ijcrp.2021.200121_bib92","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1161\/ATVBAHA.110.222067","article-title":"Telmisartan exerts anti-atherosclerotic effects by activating peroxisome proliferator-activated receptor-\u03b3 in macrophages","volume":"31","author":"Matsumura","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijcrp.2021.200121_bib93","article-title":"An insight into the role of telmisartan as PPAR\u2010\u03b3\/\u03b1 dual activator in the management of nonalcoholic fatty liver disease","volume":"12","author":"Devan","year":"2021","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.ijcrp.2021.200121_bib94","doi-asserted-by":"crossref","first-page":"110197","DOI":"10.1016\/j.mehy.2020.110197","article-title":"Exercise as medicine for COVID-19: on PPAR with emerging pharmacotherapy","volume":"143","author":"Heffernan","year":"2020","journal-title":"Med. Hypotheses"}],"container-title":["International Journal of Cardiology Cardiovascular Risk and Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772487521000234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772487521000234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:56:33Z","timestamp":1757415393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772487521000234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":94,"alternative-id":["S2772487521000234"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcrp.2021.200121","relation":{},"ISSN":["2772-4875"],"issn-type":[{"value":"2772-4875","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertension and its management in COVID-19 patients: The assorted view","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology Cardiovascular Risk and Prevention","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcrp.2021.200121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"200121"}}